A5023392870- Transplantation: Methods and Outcomes
- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Renal Transplantation Outcomes and Treatments
- Viral Infections and Immunology Research
- Hepatitis C virus research
- Cardiac Arrest and Resuscitation
- Organ Transplantation Techniques and Outcomes
- Cardiomyopathy and Myosin Studies
- Cardiac pacing and defibrillation studies
- Organ Donation and Transplantation
- Congenital Heart Disease Studies
- Cardiac Valve Diseases and Treatments
- Heart Failure Treatment and Management
- COVID-19 Clinical Research Studies
- Organ and Tissue Transplantation Research
- Cardiovascular Issues in Pregnancy
- Cardiac Arrhythmias and Treatments
- Religion, Society, and Development
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- Polyomavirus and related diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cardiac electrophysiology and arrhythmias
- Cardiac Imaging and Diagnostics
Newark Beth Israel Medical Center
2013-2024
New York University
2020-2024
International Society for Heart and Lung Transplantation
2024
IFC Research (United Kingdom)
2024
Mount Sinai Hospital
2023
NYU Langone Health
2019-2022
Miami Transplant Institute
2019-2021
National Taiwan University Hospital
2021
Bellevue Hospital Center
2020
Saint Barnabas Medical Center
2014-2018
This study aimed to evaluate the impact of cardiopulmonary bypass for thoraco-abdominal normothermic regional perfusion on metabolic milieu donation after cardiac death organ donors before transplantation.Local donor offers are assessed suitability and willingness participate. Withdrawal life-sustaining therapy is performed in operating room. After declaration circulatory a 5-minute observation period, team performs median sternotomy, ligation aortic arch vessels, initiation via central at...
Abstract Background The use of direct‐acting antivirals (DAA) has expanded transplantation from hepatitis C viremic donors (HCV‐VIR). Our team conducted an open‐label, prospective trial to assess outcomes transplanting HCV hearts. Glecaprevir/pibrentasvir (GLE/PIB) was our sole DAA. Methods Serial quantitative virus (HCV) RNA PCR obtained viral titers. Between January 2018 and June 2019, a total 50 recipients were transplanted. Of these, 22/50 (44%) HCV‐VIR, the remaining 28 non‐viremic (HCV...
Intra-aortic balloon pumps (IABPs) can be used to provide hemodynamic support in patients with end-stage heart failure as a bridge transplantation (BTT). The IABP is commonly inserted via the common femoral artery, which limit patients' mobility. Ramsey protocol, developed by critical care physical therapist, allows IABPs ambulate assistance of tilt table. aim this study was determine safety and feasibility modified protocol for early mobilization BTT. This retrospective single-center review...
Abstract Background Recent studies suggest the transplantation of Hepatitis C (HCV) hearts from viremic donors is associated with comparable 1 year survival to nonviremic donors. Though HCV viremia a known risk factor for accelerated atherosclerosis, data on cardiac allograft vasculopathy (CAV) outcomes are limited. We compared incidence CAV in heart transplant recipients (nucleic acid amplification test positive; NAT+) non‐HCV infected (NAT−). Methods retrospectively reviewed annual...
Abstract We conducted a retrospective review of thoracic transplant recipients (22 heart and 16 lung recipients) prospectively enrolled in single‐center observational study HCV NAT+ organ transplantation NAT− recipients. All were treated with 8 weeks glecaprevir‐pibrentasvir (GP) for viremia addition to standard triple immunosuppression post‐transplant. Thoracic organs used as control (24 22 recipients). Our primary outcome was assess the effect GP on tacrolimus dose requirements. Secondary...
Background The Impella (Abiomed) ventricular support system is a family of temporary mechanical circulatory (MCS) devices used to treat patients with cardiogenic shock, acute decompensation, and for high-risk percutaneous or surgical revascularization. These include the percutaneously implanted 2.5/cardiac power (CP) surgically 5.0/left direct (LD). Despite beneficial effects increased usage these devices, data assess adverse outcomes guide clinician decision-making between CP 5.0/LD are...
Quinidine is regaining interest as a life-saving and possibly exclusive treatment for inherited arrhythmia syndromes presenting with ventricular fibrillation (VF). In December 2017, the pharmaceutical manufacturer Eli Lilly announced they would cease manufacturing intravenous (IV) quinidine gluconate, rendering it unavailable worldwide. March 2019, all remaining drug supply expired. Here, we present case of idiopathic VF (IVF) electrical storm refractory to antiarrhythmic therapies,...
Background: Right ventricular (RV) dysfunction after left assist device (LVAD) implantation significantly complicates post-device management and has been shown to be associated with increased mortality. Pre-operative identification of patients who may develop post-LVAD RV is challenging. This study was designed evaluate pre-operative echocardiographic speckle tracking imaging as a predictor post operative dysfunction. Methods: Thirty-nine underwent Heartmate II LVAD placement in single...
ImmuKnow, an immune cell function assay that quantifies overall system activity can assist in post-transplant immunosuppression adjustment. However, the utility of pre-transplant ImmuKnow results representing a patient's baseline is unknown. This study sought to assess if are predictive rejection at time first biopsy our cardiac transplant population.This single center, retrospective observational consecutive patients from January 1, 2018 October 2020 who underwent orthotopic transplantation...